Jill Sindt
( out of 60 reviews )

Jill Sindt, MD

Languages spoken: English

Clinical Locations

Huntsman Cancer Institute - Cancer Hospital South

Clinic 3A, Supportive Oncology and Survivorship
801-213-4246

  • Dr. Sindt specializes in pain medicine and is skilled in procedural, medication and non-medication therapies for pain management. She has particular interest in cancer pain and practices both at the University of Utah Pain Management Center and at the Supportive Oncology and Survivorship clinic at Huntsman Cancer Hosptial.

    Specialties

    Board Certification

    American Board of Anesthesiology
    American Board of Anesthesiology (Sub: Pain Medicine)
    National Board of Medical Examiners

    Patient Rating

    4.9 /5
    ( out of 60 reviews )

    The patient rating score is an average of all responses on our patient experience survey. The rating averages scores for all questions about care from our providers.

    The scale on which responses are measured is 1 to 5 with 5 being the best score.

    Patient Comments

    Patient comments are gathered from our patient experience survey and displayed in their entirety.
    Patients are de-identified for confidentiality and patient privacy.

    August 23, 2023
    HUNTSMAN CANCER CENTER

    Knowledgeable,and Pleasent !

    August 19, 2023
    HUNTSMAN CANCER CENTER

    Dr. Sindt communicated in a caring manner, made certain the day's procedure was the correct one, made sure I was comfortable and that my ongoing care was helping me. She is easy to talk to.

    August 06, 2023
    HUNTSMAN CANCER CENTER

    The doctor was very helpful. Explained everything as far as my needs

    July 29, 2023
    HUNTSMAN CANCER CENTER

    We were on the virtual call for 45 minutes and only talked with Dr Sindt for about 5-10 minutes of that time. She was good and went over our meds with us.

    July 15, 2023
    HUNTSMAN CANCER CENTER

    Dr Sindt was very attentive to what I was saying. She explained thing so that I understood. I felt like she was compassionate for my feeling and my concerns.

    July 14, 2023
    HUNTSMAN CANCER CENTER

    Dr. Sindt is excellent. She is kind, very knowledgeable and helped me through a very difficult time in my life. I am very grateful for the care that she provided.

    July 03, 2023
    PAIN MANAGEMENT CENTER

    She is #1.I am so blessed to have her.

    May 27, 2023
    HUNTSMAN CANCER CENTER

    She is very kind and attentive.

    May 26, 2023
    HUNTSMAN CANCER CENTER

    I liked Dr. Sindt very much. She has a wonderful demeanor and excellent medical experience as well as a sense of humor.

    See More Patient Comments

  • Dr. Sindt specializes in pain medicine and is skilled in procedural, medication and non-medication therapies for pain management. She has particular interest in cancer pain and practices both at the University of Utah Pain Management Center and at the Supportive Oncology and Survivorship clinic at Huntsman Cancer Hosptial.

    Board Certification and Academic Information

    Academic Departments Anesthesiology -Primary
    Board Certification
    American Board of Anesthesiology
    American Board of Anesthesiology (Sub: Pain Medicine)
    National Board of Medical Examiners

    Education history

    Fellowship Pain Medicine - University of Utah Fellow
    University of Utah Chief Resident
    Residency Anesthesiology - University of Utah Resident
    Intermountain Medical Center Transitional Transitional Internship
    Research Fellow NIH Summer Research Fellowship in Pediatric Nutrition: the effects of a high-protein, low-carbohydrate diet on weight , lipid profiles, insulin profiles and satiety in obese adolescents. - University of Colorado Health Sciences Center, School of Medicine Research Fellow
    Medicine - University of Colorado School of Medicine M.D.
    Undergraduate Spanish Language and Literature, Summa Cum Laude - Colorado State University B.A.

    Selected Publications

    Journal Article

    1. Sindt JE, Fitzgerald LA, Kuznicki J, Prelewicz S, Odell DW, Brogan SE (2023). Antiplatelet and Wound Healing Implications of Immunotherapy and Targeted Cancer Therapies in the Perioperative Period. Anesthesiology, 139(4), 511-522. (Read full article)
    2. Brogan SE, Odell DW, Sindt JE, Yi I, Chrisman OM, Zhang C, Presson AP (2022). Dorsal Versus Ventral Intrathecal Catheter Tip Location and Effect on Dose Escalation and Opioid Use in Patients With Cancer Pain. Neuromodulation, 26(6), 1233-1239. (Read full article)
    3. Brogan SE, Sindt JE, Odell DW, Gulati A, Dupoiron D (2022). Controversies in intrathecal drug delivery for cancer pain. Reg Anesth Pain Med, 48(6), 319-325. (Read full article)
    4. Jenkinson RH, Wendahl A, Zhang Y, Sindt JE (2023). Creating Realistic Definitions of Clinically Significant Radiographic Lead Migration - A Response to "Migration of Epidural Leads During Spinal Cord Stimulator Trials" [Response to Letter]. J Pain Res, 16, 513-514. (Read full article)
    5. Jenkinson RH, Wendahl A, Zhang Y, Sindt JE (2022). Migration of Epidural Leads During Spinal Cord Stimulator Trials. J Pain Res, 15, 2999-3005. (Read full article)
    6. Sindt JE, Odell DW, Tariq R, Presson AP, Zhang C, Brogan SE (2021). Initial Intrathecal Dose Titration and Predictors of Early Dose Escalation in Patients With Cancer Using a 100:1 Oral to Intrathecal Morphine Conversion Ratio. Neuromodulation, 24(7), 1157-1166. (Read full article)
    7. Brogan SESindt JE, Odell DW (2021). Quantitative Assessment of the Incidence of Persistent Orthostatic Hemodynamic Changes After Celiac Plexus Neurolysis: A Prospective Case Series. A A Pract, 15(5), e01470.
    8. Brogan SE, Sindt JE, Odell DW (2021). Quantitative Assessment of the Incidence of Persistent Orthostatic Hemodynamic Changes After Celiac Plexus Neurolysis: A Prospective Case Series. A A Pract, 15(5), e01470. (Read full article)
    9. Odell DW, Albrechtsen RD, Sindt JE, Gole R, Brown S, Parsons MW, Paxton AB, Sarkar V, Lloyd S, Brogan SE, Tao R (2021). The Effect of Measured Radiotherapy Dose on Intrathecal Drug Delivery System Function. Neuromodulation, 24(7), 1204-1208. (Read full article)
    10. Sindt JE, Odell DW, Dalley AP, Brogan SE (2020). Initiation of Intrathecal Drug Delivery Dramatically Reduces Systemic Opioid Use in Patients With Advanced Cancer. Neuromodulation, 23(7), 978-983.
    11. Sindt JE, Odell DW, Dalley AP, Brogan SE (2020). Initiation of Intrathecal Drug Delivery Dramatically Reduces Systemic Opioid Use in Patients With Advanced Cancer. Neuromodulation, 23(7), 978-983. (Read full article)
    12. Sindt JE, Larsen SD, Dalley AP, Collier WH, Brogan SE (2020). The Rate of Infectious Complications After Intrathecal Drug Delivery System Implant for Cancer-Related Pain Is Low Despite Frequent Concurrent Anticancer Treatment or Leukopenia. Anesth Analg, 131(1), 280-287.
    13. Sindt JE, Larsen SD, Dalley AP, Collier WH, Brogan SE (2020). The Rate of Infectious Complications After Intrathecal Drug Delivery System Implant for Cancer-Related Pain Is Low Despite Frequent Concurrent Anticancer Treatment or Leukopenia. Anesth Analg, 131(1), 280-287. (Read full article)
    14. Brogan SE, Sindt JE, Jackman CM, White J, Wilding V, Okifuji A (2020). Prospective Association of Serum Opioid Levels and Clinical Outcomes in Patients With Cancer Pain Treated With Intrathecal Opioid Therapy. Anesth Analg, 130(4), 1035-1044.
    15. Robert A Swarm, MD Judith A Paice, PhD, RN Doralina L Anghelescu, MD Madhuri Are, MD Justine Yang Bruce, MD Sorin Buga, MD Marcin Chwistek, MD Charles Cleeland, PhD David Craig, PharmD Ellin Gafford, MD Heather Greenlee, PhD, ND Eric Hansen, MD Arif H Kamal, MD, MBA, MHS Mihir M Kamdar, MD Susan LeGrand, MD Sean Mackey, MD, PhD M Rachel McDowell, MSN, ACNP-BC Natalie Moryl, MD Lisle M Nabell, MD Suzanne Nesbit, PharmD, BCPS Nina OConnor, MD Michael W Rabow, MD Elizabeth Rickerson, MD Rebecca Shatsky, MD Sindt Jill, MD Susan G Urba, MD Jeanie M Youngwerth, MD Lydia J Hammond, MBA and Lisa A Gurski, PhD (2019). NCCN Clinical Practice Guidelines in Oncology - Adult Cancer Pain, Version 3.2019. J Natl Compr Canc Netw, 17(8), 977-1007.
    16. Swarm RA, Paice JA, Anghelescu DL, Are M, Bruce JY, Buga S, Chwistek M, Cleeland C, Craig D, Gafford E, Greenlee H, Hansen E, Kamal AH, Kamdar MM, LeGrand S, Mackey S, McDowell MR, Moryl N, Nabell LM, Nesbit S, BCPS, OConnor N, Rabow MW, Rickerson E, Shatsky R, Sindt J, Urba SG, Youngwerth JM, Hammond LJ, Gurski LA (2019). Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 17(8), 977-1007. (Read full article)
    17. Iacob E, Hagn EE, Sindt J, Brogan S, Tadler SC, Kennington KS, Hare BD, Bokat CE, Donaldson GW, Okifuji A, Junkins SR (2017). Tertiary Care Clinical Experience with Intravenous Lidocaine Infusions for the Treatment of Chronic Pain. Pain Med, 19(6), 1245-1253. (Read full article)
    18. Sindt JE, Brogan SE (2016). Interventional Treatments of Cancer Pain. Anesthesiol Clin, 34(2), 317-39. (Read full article)
    19. Sindt J (2016). Managing Pain Before It Manages You. J Pain Palliat Care Pharmacother, 30(2), 155. (Read full article)

    Letter

    1. Abdullah N, Sindt JE, Whittle J, Anderson JS, Odell DW, Mahan M, Brogan SE (2022). Impact of neuromodulation on opioid use, adjunct medication use, and pain control in cancer-related pain: a retrospective case series. [Letter to the editor]. Pain Med, 24(7), 903-906. (Read full article)

  • News & Podcasts